PHOTOSTABILITY TESTING OF DRUG SUBSTANCES AND DRUG PRODUCTS IN UK PHARMACEUTICAL LABORATORIES

被引:9
|
作者
ANDERSON, NH
JOHNSTON, D
MCLELLAND, MA
MUNDEN, P
机构
关键词
DRUG SUBSTANCES; PHARMACEUTICAL PRODUCTS; PHOTOSTABILITY; LIGHT TESTING; PHOTOCHEMICAL DEGRADATION;
D O I
10.1016/0731-7085(91)80245-5
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Results of a survey on photostability testing of drug substances and products by UK pharmaceutical laboratories are presented. The results indicate diverse practices in the form of presentation of the product and particularly in exposure to light (as measured in lx days), although there was more consistency in analytical methods and in the analytical criteria used to classify products as stable or unstable for those laboratories adopting this type of classification. A majority of laboratories use daylight in addition to artificial light sources for tests on drug substances and products. Artificial daylight fluorescent tubes and xenon lamps are the most widely used sources of artificial light and both should provide a reasonable simulation of natural light. All laboratories intend their photostability tests to represent light exposure which exceeds that expected to occur in practice but the tests actually applied vary widely in severity as shown in the wide range in light exposure (8-4500 klx days). Therefore the classification of products as stable or unstable needs to be considered carefully in relation to the severity of the test used. Testing procedures for drug substances are broadly similar to those used for drug products. It is concluded that the variation in testing procedure is the result of differing perceptions regarding product exposure in practical usage and the absence of regulatory guidelines.
引用
收藏
页码:443 / 449
页数:7
相关论文
共 50 条
  • [1] THE VALIDATION OF ANALYTICAL METHODS FOR DRUG SUBSTANCES AND DRUG PRODUCTS IN UK PHARMACEUTICAL LABORATORIES
    CLARKE, GS
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1994, 12 (05) : 643 - 652
  • [2] 'Quality by Design' approach for the analysis of impurities in pharmaceutical drug products and drug substances
    Dispas, Amandine
    Avohou, Hermane T.
    Lebrun, Pierre
    Hubert, Philippe
    Hubert, Cedric
    [J]. TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2018, 101 : 24 - 33
  • [3] Strategies for Identity Testing of Therapeutic Oligonucleotide Drug Substances and Drug Products
    Capaldi, Daniel
    Akhtar, Nadim
    Atherton, Tom
    Benstead, David
    Charaf, Ayman
    De Vijlder, Thomas
    Heatherington, Carl
    Hoernschemeyer, Joerg
    Jiang, Hong
    Rieder, Ulrike
    Ring, Francis
    Peter, Robert
    Stolee, Jessica A.
    Wechselberger, Rainer
    [J]. NUCLEIC ACID THERAPEUTICS, 2020, 30 (05) : 249 - 264
  • [4] Implications of In-Use Photostability: Proposed Guidance for Photostability Testing and Labeling to Support the Administration of Photosensitive Pharmaceutical Products, Part 1: Drug Products Administered by Injection
    Baertschi, Steven W.
    Clapham, David
    Foti, Chris
    Jansen, Patrick J.
    Kristensen, Solveig
    Reed, Robert A.
    Templeton, Allen C.
    Tonnesen, Hanne Hjorth
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (11) : 3888 - 3899
  • [5] Implications of In-Use Photostability: Proposed Guidance for Photostability Testing and Labeling to Support the Administration of Photosensitive Pharmaceutical Products, Part 3. Oral Drug Products
    Allain, Leonardo
    Baertschi, Steven W.
    Clapham, David
    Foti, Chris
    Lantaff, Wendy M.
    Reed, Robert A.
    Templeton, Allen C.
    Tonnesen, Hanne Hjorth
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 105 (05) : 1586 - 1594
  • [6] Photostability and Photostabilization of Drugs and Drug Products
    Ahmad, Iqbal
    Ahmed, Sofia
    Anwar, Zubair
    Sheraz, Muhammad Ali
    Sikorski, Marek
    [J]. INTERNATIONAL JOURNAL OF PHOTOENERGY, 2016, 2016
  • [7] Implications of In-Use Photostability: Proposed Guidance for Photostability Testing and Labeling to Support the Administration of Photosensitive Pharmaceutical Products, Part 2: Topical Drug Product
    Baertschi, Steven W.
    Clapham, David
    Foti, Chris
    Kleinman, Mark H.
    Kristensen, Solveig
    Reed, Robert A.
    Templeton, Allen C.
    Tonnesen, Hanne Hjorth
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (09) : 2688 - 2701
  • [8] A Critical Assessment of the ICH Guideline on Photostability Testing of New Drug Substances and Products (Q1B): Recommendation for Revision
    Baertschi, Steven W.
    Alsante, Karen M.
    Tonnesen, Hanne H.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (07) : 2934 - 2940
  • [9] Impurities in Oligonucleotide Drug Substances and Drug Products
    Capaldi, Daniel
    Teasdale, Andy
    Henry, Scott
    Akhtar, Nadim
    den Besten, Cathaline
    Gao-Sheridan, Samantha
    Kretschmer, Matthias
    Sharpe, Neal
    Andrews, Ben
    Burm, Brigitte
    Foy, Jeffrey
    [J]. NUCLEIC ACID THERAPEUTICS, 2017, 27 (06) : 309 - 322